From innovation to impact
"Innovation that changes lives requires ingenuity—and so much more."

— Steve Davis
PATH President and CEO

ON THE COVER: A family in Laos holds their vaccination papers during an immunization campaign against Japanese encephalitis.

Cover photo: PATH/Aaron Joel Santos
From innovation to impact

PATH'S 2015 ANNUAL REPORT
Malaria
elimination

IMPACT AT A GLANCE

20+
Countries where PATH works to eliminate malaria.

93%
Drop in malaria parasites in children in Zambia’s Southern Province following a village-by-village initiative to prevent and treat the disease.

6
African countries now using real-time data to improve malaria case management through an electronic data system.

PATH/Gabe Bienczycki
Vaccines and Immunization

**IMACT AT A GLANCE**

**24+**
Vaccines in PATH’s portfolio currently in development or already in use against 15 diseases.

**235 million**
Africans reached with meningitis A vaccine since 2010.

**232 million**
Children in Asia reached with Japanese encephalitis vaccine since 2003.

LEARN MORE PAGE 16
WOMEN’S AND GIRLS’ HEALTH

IMPROCT AT A GLANCE

50+
Designs PATH developed and tested in creating the Woman’s Condom, which protects against both pregnancy and HIV.

275,000
Doses of a new form of injectable contraceptive administered in four African countries.

25+
Countries where a new one-size-fits-most diaphragm is now available.
Nutrition and child health
IMPRCT
AT A GLANCE

4
Countries where PATH is working to scale up human milk banking and breastfeeding promotion.

9 million
Infants in Africa and Asia who have difficulty breastfeeding and could receive lifesaving nourishment through a new feeding cup.

5 minutes
Time it takes to produce chlorine from a new water treatment product to treat up to 200 liters of water.
Message from PATH’s president and board chair

MILESTONES IN
Malaria elimination

MILESTONES IN
Vaccines and immunization

MILESTONES IN
Women’s and girls’ health

MILESTONES IN
Nutrition and child health

Thank you to our supporters

Finances

Leadership

PATH’s global presence

Key partners and funders
The act of invention is just the beginning

Innovation is sometimes defined as the “eureka moment”—that thunderbolt of discovery and revelation when a new idea or solution takes shape.

At PATH, we know that innovation that changes lives requires ingenuity—and so much more.

Like patience, perseverance, and partnerships. And years of careful, methodical work that paves the way for impact by clearing the obstacles that stand between our brightest ideas and the people who can use them to transform their futures.

We are proud to share with you our latest annual report, including some of the years-in-the-making milestones PATH and our partners celebrated in 2015:

• The virtual disappearance of deadly meningitis A across large stretches of Africa.

• Important advances in malaria control and elimination that can hasten the end of the disease, including the first malaria vaccine candidate recommended for pilot use by the World Health Organization.

• The rollout of a new contraceptive option that reached thousands of African women who had never used modern family planning methods.

• The launch of a low-cost water treatment product that can produce more than 50 gallons of clean water for schools and communities at the touch of a button.

Over the past five years, PATH and our partners have reached an average of 150 million people per year with lifesaving technologies and approaches like these—innovations that reflect our unwavering commitment to the idea that everyone deserves an equal chance for a healthy life.
2015
BY THE NUMBERS

150 million+
Average number of people reached by PATH and our partners per year since 2011

108
System and service innovation projects in our portfolio

81
Technologies and products in our innovation pipeline

2,000+
Partners around the world

100,000+
Health care providers, policymakers, advocates, and others we trained

Illustrations from the Noun Project. Clockwise from top left: Hea Poh Lin, Oliviu Stoian, Démarque Toi, Sergey Demushkin, Jaclyne Ooi, Sergey Demushkin, Richard Slater.
Accelerating our impact

With our crosscutting expertise and a global network of more than 2,000 partner organizations, PATH drives health innovation that reaches more people more quickly to improve health and unlock human potential.

Over the past year, we have taken some exciting steps that will accelerate our ability to reach people with transformative health solutions.

PATH launched our new Center for Vaccine Innovation and Access and our Center for Malaria Control and Elimination to make our work even more effective. These centers bring together our multidisciplinary expertise and multiple projects under unified teams of PATH experts. They will work at every step of the complex process of researching, developing, and introducing vaccines and across the spectrum of tools and approaches needed to end malaria for good.

We also joined the global effort to confront emerging health threats such as Zika and Ebola. Working with the US Centers for Disease Control and Prevention and country partners in Senegal, Tanzania, and Vietnam, PATH is helping to strengthen health information systems, laboratory networks, and disease surveillance capacity. These improved systems will equip countries to prevent, detect, and respond to cross-border pandemic threats and public health emergencies.

Thanks to you

Our ability to reach the most vulnerable people with lifesaving innovations—to empower countries and communities to build the foundations of good health—is possible because of you, our partners and supporters. We are profoundly grateful for your support.

Together, we are harnessing the power of innovation to ensure that our collective resolve and “eureka moments” lead to a world where health is within reach for everyone.

Steve Davis
President and CEO

Dean Allen
Chair, Board of Directors
Data collectors in Zambia walk from house to house gathering real-time data on malaria cases and transmitting the information by mobile phone to improve tracking and treatment of the disease.
Opportunity
Eliminate malaria, a disease that claimed the lives of more than 400,000 people last year—mostly African children under age five.

Innovations
PATH is a global leader in the battle to control and eliminate malaria. We bring an array of innovations to the fight, including an unparalleled portfolio of malaria vaccine candidates and community-level strategies to detect, track, and treat every last case of malaria transmission. Through our Center for Malaria Control and Elimination, we harness our scientific expertise, global partnerships, and on-the-ground experience to pursue a singular goal: a world without malaria.

2015 impact
• The first malaria vaccine candidate, RTS,S, has been recommended by the World Health Organization for a pilot implementation program in sub-Saharan Africa following a positive opinion from European regulators on its use in children. PATH and our development partner, GlaxoSmithKline, worked together with other collaborators for 15 years to develop RTS,S. If the program is fully funded and RTS,S licensed for use, it would also be the first vaccine against a human parasite.
• In Zambia, our groundbreaking approach to eliminating malaria—building a high-quality disease surveillance system, testing for and treating the disease, and using mass treatment campaigns to treat whole communities—has proven so successful that Zambia is making it a central feature of its nationwide elimination program. One-quarter of the nation’s health facilities now use rapid data reporting via mobile phone to improve malaria tracking and treatment.
• Our manufacturing partner, Sanofi, shipped 51 million antimalarial treatments—made with a semisynthetic form of artemisinin—to 23 African countries. PATH and our partners developed the new form of artemisinin to ensure a more stable source of this key ingredient in malaria treatments.
• Health officials in six African countries are using real-time data to improve the quality of malaria case management through an innovative electronic data system developed and launched by MalariaCare, a PATH-led partnership.
• PATH accelerated the development and availability of high-quality diagnostic tests that can detect low levels of malaria infection and asymptomatic cases, in addition to tests that make it easier to cure malaria.

For a list of our key partners and funders, see page 28.
PATH accelerated the delivery of a vaccine against deadly Japanese encephalitis in Laos and Cambodia, and our vaccine technologies helped ensure the vaccine’s safe arrival in each community.
Opportunity
Reach every child around the world with vaccines to prevent diseases that now kill 1.5 million children every year.

Innovations
PATH has reached billions of people with lifesaving vaccines and vaccine technologies. With our partners, we work on early discovery, testing, regulatory issues, manufacturing, and vaccine introduction and delivery to protect against 15 different diseases. Our work has contributed to a more than 50 percent reduction in child mortality over the past three decades.

2015 impact
• The MenAfriVac® vaccine has reached more than 235 million Africans, leading to the disappearance of meningitis A epidemics in Africa wherever the vaccine has been introduced. The vaccine was developed through a partnership among PATH, the World Health Organization, and Serum Institute of India Pvt. Ltd. Preparations are under way to include the vaccine as part of routine national immunization programs. A PATH-supported vaccine candidate against other causes of epidemic meningitis in Africa is ready to enter clinical trials in 2016.
• PATH also helped expand access to MenAfriVac through an innovative approach that allows transport and distribution of the vaccine in remote areas without ice or refrigeration.
• Laos launched a nationwide immunization campaign to protect 1.5 million children against Japanese encephalitis (JE), an incurable and deadly disease. Cambodia followed suit in 2016. For more than a decade, we worked with partners to identify and accelerate the delivery of an affordable JE vaccine and support country-led efforts that have reached more than 232 million children across Southeast Asia to date.
• PATH and our partners advanced clinical trials of seven vaccine candidates to protect against the two top killers of children—pneumonia and diarrheal disease.
• We redoubled our commitment to reach every child with lifesaving vaccines by launching the new Center for Vaccine Innovation and Access. The center brings together PATH’s vaccine experts into a single team working across every stage of the long, complex process of vaccine research, development, and introduction.

*MenAfriVac is a registered trademark of Serum Institute of India Pvt. Ltd.*

For a list of our key partners and funders, see page 28.
A village health worker in Uganda counsels a patient on family planning before administering the new injectable contraceptive called Sayana Press.
Opportunity
Create new contraceptive options that empower the estimated 225 million women worldwide who want to avoid pregnancy but do not use or have access to modern contraception.

Innovations
Access to the right contraceptive can change a woman’s life. PATH and our partners created and championed three new family planning solutions: Sayana® Press, an all-in-one injectable contraceptive that is easy to use, transport, and distribute; the single-size Caya® contoured diaphragm with a design inspired and informed by input from women and health care providers; and the Woman’s Condom, a new female condom that offers dual protection against pregnancy and sexually transmitted infections, including HIV.

2015 impact
• Nearly 275,000 doses of Sayana Press were administered in four African countries through country-led partnerships coordinated by PATH. Nearly 75,000 of the women reached had never used modern contraception before. Hundreds of women in Senegal and Uganda also took part in studies on self-injection. Early results indicate that most women can successfully administer the contraceptive themselves, potentially increasing women’s control of and access to family planning. Sayana Press self-injection was approved by the United Kingdom’s regulatory authority, and several European Union countries have also approved self-injection.
• Caya became the first new diaphragm design to enter the US market in more than 50 years. Its one-size-fits-most design was developed and refined by PATH and our partners through nearly 200 prototype designs. Caya is now available in more than 25 countries, and work continues to bring this new contraceptive option to additional countries.
• The Woman’s Condom achieved prequalification by the World Health Organization and the United Nations Population Fund, a critical step toward increasing access worldwide. A PATH-led product development partnership paved the way for increased manufacturing capacity and regulatory approvals needed to expand access to new markets. The Woman’s Condom is now being introduced in African countries.

Sayana Press is a registered trademark of Pfizer Inc.; Caya is a registered trademark of Kessel medintim GmbH.

For a list of our key partners and funders, see page 28.
Better nutrition + clean water = healthy kids

This portable device produces chlorine to quickly treat community drinking water in low-resource and disaster-stricken settings.
Opportunity
Prevent the deaths of millions of newborns and children who die in low-income countries each year because of undernutrition and unsafe drinking water.

Innovations
Our technologies and approaches help give children the best possible start in life. Solutions pioneered by PATH and our partners include: the NIFTY cup, a low-cost cup used for hand expression of breast milk and feeding infants unable to breastfeed; a system to manage the safe pasteurization of human breast milk using mobile phone–based technology; the MSR® SE200™ Community Chlorine Maker, which can be used to produce safe drinking water at community wells, kiosks, and schools; and sustainable innovations in nutrition to improve children’s diets.

2015 impact
- PATH is collaborating with partners to bring a new feeding cup to market based on the NIFTY cup design to reach the 9 million infants in Africa and Asia who have difficulty breastfeeding. PATH is validating use of the NIFTY cup in sub-Saharan Africa to provide evidence that will inform future use of this lifesaving device for preterm infants.
- To increase access to human milk for vulnerable infants, we are leading efforts in South Africa and other countries to scale up an integrated package of human milk banking and breastfeeding promotion to strengthen nutrition and newborn care health systems. We are also working to transfer affordable, safe pasteurization technologies to manufacturers at low cost to ensure sustainability.
- The MSR SE200 Community Chlorine Maker was launched in 2015, the result of a five-year, cross-sector partnership to bring low-cost community water solutions to the global market. Using salt, water, and a 12-volt battery, the device produces enough chlorine to treat up to 200 liters of water in just five minutes.
- PATH is working with communities in Ghana on strategies to incorporate akokono, a type of edible larvae, into people’s diets. These protein- and vitamin-rich grubs are considered a delicacy and offer an environmentally friendly way to improve nutrition. New approaches are being tested for potential use in community settings that may offer a new source of income for women through microfarming, processing, and sales.

MSR SE200 is a registered trademark of Mountain Safety Research, a Division of Cascade Designs, Inc.

For a list of our key partners and funders, see page 28.
Thank you to our supporters

Some think the global health challenges the world faces today are too big to solve. Not you. And not PATH.

Your support makes our innovative work possible. Together, we are creating solutions that empower people everywhere to transform their own health and futures.

PATH’s commitment to good financial stewardship has earned us the highest possible rating from Charity Navigator—for the 12th year in a row. It is a designation received by less than 1 percent of the more than 8,000 charities rated by America’s largest independent evaluator of nonprofits.

For a list of our supporters, please visit: www.path.org/annual-report/2015/
Finances

2015 financial summary

**REVENUE (in thousands)**

<table>
<thead>
<tr>
<th>Source</th>
<th>Revenue (in thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundations</td>
<td>$157,504</td>
</tr>
<tr>
<td>US government</td>
<td>74,836</td>
</tr>
<tr>
<td>Other governments, nongovernmental organizations (NGOs), multilaterals</td>
<td>40,367</td>
</tr>
<tr>
<td>Individuals/other</td>
<td>9,960</td>
</tr>
<tr>
<td>Investments</td>
<td>4,411</td>
</tr>
<tr>
<td>Corporations</td>
<td>1,570</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td><strong>$288,648</strong></td>
</tr>
</tbody>
</table>

**EXPENSES (in thousands)**

**Program-related:**

<table>
<thead>
<tr>
<th>Category</th>
<th>Expenses (in thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product development</td>
<td>$62,892</td>
</tr>
<tr>
<td>Public health</td>
<td>50,298</td>
</tr>
<tr>
<td>International development</td>
<td>24,017</td>
</tr>
<tr>
<td>Cross-program initiatives</td>
<td>7,817</td>
</tr>
<tr>
<td>Program development</td>
<td>2,441</td>
</tr>
<tr>
<td>Subawards to program partners</td>
<td>97,234</td>
</tr>
<tr>
<td><strong>Subtotal program-related</strong></td>
<td><strong>$244,699</strong></td>
</tr>
<tr>
<td>Administrative</td>
<td>$36,626</td>
</tr>
<tr>
<td>Fundraising</td>
<td>3,569</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>$284,894</strong></td>
</tr>
</tbody>
</table>

**ASSETS (in thousands)**

<table>
<thead>
<tr>
<th>Asset</th>
<th>Total (in thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$118,096</td>
</tr>
<tr>
<td>Invested grant funds</td>
<td>198,894</td>
</tr>
<tr>
<td>Contributions and awards receivable</td>
<td>278,519</td>
</tr>
<tr>
<td>Other</td>
<td>24,924</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$620,433</strong></td>
</tr>
</tbody>
</table>

**LIABILITIES AND NET ASSETS (in thousands)**

<table>
<thead>
<tr>
<th>Liability</th>
<th>Total (in thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total liabilities</td>
<td>$48,928</td>
</tr>
<tr>
<td><strong>Net assets:</strong></td>
<td></td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$546,620</td>
</tr>
<tr>
<td>Unrestricted</td>
<td>21,495</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,390</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$571,505</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td><strong>$620,433</strong></td>
</tr>
</tbody>
</table>

**Sources of Revenue**

- 54.6% Foundations
- 25.9% US government
- 14.0% Other governments, NGOs, multilaterals
- 3.5% Individuals/other
- 1.5% Investments
- 0.5% Corporations

**Use of Funds**

- 50.4% Product development
- 30.3% Public health
- 16.3% International development
- 3.0% Cross-program initiatives

**Expense Allocation**

- 85.9% Program-related
- 12.9% Administrative
- <1.3% Fundraising

*Use of funds includes direct expenses and funds subawarded to partners.

Figures are presented in US dollars.

Notes: The above financial summary is based on PATH’s audited financial statements, which are audited by the firm Clark Nuber P.S. Full copies are available on our website at www.path.org.

PATH is an international, nonprofit, nongovernmental organization. Our mission is to improve the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors. Contributions to PATH are tax-exempt under US IRS code 501(c)(3).
Leadership

Board of Directors

Jo Addy, MBA, MPA
United States
Founder and Managing Director
Alsweb Business Advantage
Upper Marlboro, MD USA

Dean Allen CHAIR
United States
CEO
McKinstry
Seattle, WA USA

Phyllis Campbell, MBA
United States
Chairman, Pacific Northwest
JPMorgan Chase & Co.
Seattle, WA USA

Alex Chika Ezeh, PhD, MSc
Nigeria
Executive Director
African Population & Health Research Center
Nairobi, Kenya

George Gotsadze, MD, PhD VICE CHAIR
Georgia
Director
Curatio International Foundation
Tbilisi, Georgia

David King, JD TREASURER
United States
Chairman and CEO
LabCorp
Burlington, NC USA

Gary Locke, JD
United States
Former Governor of Washington State
Former US Secretary of State for Commerce
Former US Ambassador to China
Seattle, WA USA

Tsitsi Masiyiwa, MBA
Zimbabwe
Cofounder and Executive Chair
Higher Life Foundation
Johannesburg, South Africa

Bruce McNamer, JD, MBA
United States
CEO/President
Community Foundation for the National Capital Region
Washington, DC USA

Laurie Michaels, PhD
United States
Founder, CEO
Open Road Alliance
Colorado, USA

Felix Olale, MD, PhD SECRETARY
Kenya
Partner
LeapFrog Investments
Johannesburg, South Africa
Nairobi, Kenya

Kevin Reilly, MBA
United States
Former President
Wyeth Vaccines and Nutrition
Rosemont, PA USA

Dennis Schmatz, PhD
United States
Former Vice President of Infectious Disease Research and Animal Health
Merck & Co. Inc.
New Jersey, USA

Peter Smith, CBE, DSc, FMedSci
United Kingdom
Professor
MRC Tropical Epidemiology Group
London School of Hygiene & Tropical Medicine
London, UK

Rajendra Vattikuti, MS
United States
Founder and Former President and CEO
Covansys
Founder
Vattikuti Foundation
Southfield, MI USA

Ireena Vittal, MBA
India
Former Partner
McKinsey and Company
New Delhi, India

Yehong Zhang, PhD, MBA
China/United States
CEO
Luye Pharmaceutical Group (International)
Shanghai, China
New Jersey, USA
Executive Team

Steve Davis, MA, JD  
President and CEO

Amie Batson, MBA  
Chief Strategy Officer  
Vice President, Strategy and Learning

Kathy Cahill, MPH  
Vice President, International Development

David Fleming, MD  
Vice President, Public Health

David C. Kaslow, MD  
Vice President, Product Development  
Director, Center for Vaccine Innovation and Access

Dan Laster, JD  
General Counsel  
Vice President, Business and Research Affairs

Mark D. Murray  
Vice President, Global Engagement and Communications

Kathryn O’Driscoll  
Chief Human Resources Officer

Olivia Polius  
Chief Financial Officer  
Vice President, Finance, Technology, and Infrastructure

Program Leaders

INTERNATIONAL DEVELOPMENT

Mona Byrkit, MPH  
Mekong Region

Kateryna (Katya) Gamazina, MD  
Ukraine

Philippe Guinot, MBA  
Senegal

Trad Hatton, MA, MHS  
Democratic Republic of the Congo

Neeraj Jain, MBA  
India

Tirsit Grishaw Legesse, MS  
Ethiopia

Zahra Mkomwa, MD, MPH  
Tanzania

Nanthalile Mugala, MD, MMed  
Zambia

Emmanuel Mugisha, PhD, MPH  
Uganda

Rikka Trangsrud, MA  
Kenya

To be hired  
South Africa

PRODUCT DEVELOPMENT

Deborah Atherly, PhD  
Policy, Access, and Introduction, Center for Vaccine Innovation and Access

Ashley Birkett, PhD  
Malaria Vaccine Initiative and Malaria Vaccines, Center for Vaccine Innovation and Access

Tala de los Santos, MS, MBA  
Diagnostics

John Konz, PhD  
Integrated Portfolio and Financial Management, Center for Vaccine Innovation and Access

Jessica Milman, MPH  
Office of Product Development

David Shultz, PhD, MS, MBA  
Devices and Tools  
Drug Development

YanXiang (Michael) Wang, MBA  
China

PUBLIC HEALTH

Cyril Engmann, MD, FAAP  
Maternal, Newborn, and Child Health and Nutrition

Jane Hutchings, MPH  
Reproductive Health

Katharine Kreis, MPH  
Nutrition Innovations

Helen McGuire, MHA  
Noncommunicable Diseases

Dykki Settle  
Digital Health Solutions

Larry Slutsker, MD, MPH  
Malaria and Neglected Tropical Diseases  
Center for Malaria Control and Elimination

Johannes van Dam, MD, MSc  
Health Systems Innovation and Delivery  
HIV/AIDS and Tuberculosis
PATH’s global presence

PATH works in more than 70 countries to accelerate innovation that saves lives and improves health, especially among women and children.

Our country-based projects tackle top-priority health challenges at the local and national levels in collaboration with governments, private-sector partners, and others. Our global partnerships address international-level health priorities, policies, and financing in collaboration with policymakers, funders, and others.
Office locations

Belgium | Brussels
China | Beijing
Democratic Republic of the Congo | Bunia, Kinshasa, Kisangani, Lubumbashi
Ethiopia | Addis Ababa, Injibara
Ghana | Accra
India | Bangalore, Lucknow, Mumbai, New Delhi
Kenya | Bungoma, Busia, Kakamega, Kisumu, Migori, Nairobi, Nyamira, Oyugis
Malawi | Lilongwe
Mozambique | Maputo, Matola
Myanmar | Yangon
Peru | Lima
Senegal | Dakar
South Africa | Empangeni, Johannesburg, Kuruman, Sedibeng, Witbank
Switzerland | Geneva
Tanzania | Arusha, Dar es Salaam
Uganda | Kampala, Mbarara
Ukraine | Kyiv
United States | San Francisco, Seattle (headquarters), Washington, DC
Vietnam | Hanoi, Ho Chi Minh City
Zambia | Livingstone, Lusaka
**Malaria elimination**

**KEY PARTNERS:** National malaria programs, ministries of health, scientists, and local partners in 29 countries; African Leaders Malaria Alliance; Akros Inc.; FIND; Fraunhofer Center for Molecular Biotechnology; GlaxoSmithKline; Global Fund to Fight AIDS, Tuberculosis and Malaria; Harvard School of Public Health; Imperial College London; Jenner Institute; Liverpool School of Tropical Medicine; Malaria No More; Medical Care Development International; National Institute of Allergy and Infectious Diseases; Population Services International; QIMR Berghofer Medical Research Institute; Radboud University Medical Centre; Roll Back Malaria Partnership; Sanofi; Save the Children; Speak Up Africa; Swiss Tropical and Public Health Institute; Tableau Foundation; Tulane University School of Public Health and Tropical Medicine; UK Department for International Development (DFID); United Nations Children’s Fund; United Nations Special Envoy’s Office for Malaria; US National Institutes of Health; US President’s Malaria Initiative; Walter Reed Army Institute of Research; World Health Organization (WHO).

**KEY FUNDERS:** Bill & Melinda Gates Foundation; DFID; ExxonMobil Foundation; US Agency for International Development (USAID)/US President’s Malaria Initiative; Vattikuti Foundation; individual contributors and family foundations.

**Vaccines and immunization**

**KEY PARTNERS:** Meningitis vaccines: Serum Institute of India Pvt. Ltd.; WHO; ministries of health in Africa; dozens of global collaborators. Japanese encephalitis (JE): Chengdu Institute of Biological Products Co., Ltd.; China National Biotec Group Co., Ltd.; Gavi, the Vaccine Alliance; WHO; ministries of health in Asia. Pneumonia and diarrheal disease vaccine candidates: Bharat Biotech International Ltd.; Boston Children’s Hospital; icddr,b; India’s Department of Biotechnology; Johns Hopkins University; Respiratory and Meningeal Pathogens Research Unit at Chris Hani Baragwanath Academic Hospital; Scandinavian Biopharma; Serum Institute of India Pvt. Ltd.; Society for Applied Studies; University of Gothenburg; US Naval Medical Research Center; Walter Reed Army Institute of Research; Wuhan Institute of Biological Products Co., Ltd.

**KEY FUNDERS:** Meningitis vaccines: Bill & Melinda Gates Foundation; DFID; Gavi, the Vaccine Alliance; Michael & Susan Dell Foundation; Shefa Fund hosted by the Swiss Philanthropy Foundation; USAID; US Centers for Disease Control and Prevention; individual contributors and family foundations. JE: Bill & Melinda Gates Foundation; Microsoft; individual contributors and family foundations. Pneumonia and diarrheal disease vaccine candidates: Bill & Melinda Gates Foundation; DFID; Research Council of Norway; Wellcome Trust.

**Women’s and girls’ health**

**KEY PARTNERS:** Sayana® Press: Ministries of health and implementing partners in Burkina Faso, Niger, Senegal, and Uganda; DFID; Pfizer Inc.; United Nations Population Fund. Caya®: CONRAD; Kessel medintim GmbH. Woman’s Condom: CONRAD; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Shanghai Dahua Medical Apparatus Co., Ltd.

**KEY FUNDERS:** Sayana® Press: Bill & Melinda Gates Foundation; Children’s Investment Fund Foundation; USAID; individual contributors and family foundations. Caya®: USAID; individual contributors and family foundations. Woman’s Condom: Netherlands Ministry of Foreign Affairs; Universal Access to Female Condoms; USAID; The William and Flora Hewlett Foundation; individual contributors and family foundations.

**Nutrition and child health**

**KEY PARTNERS:** NIFTY cup: Laerdal Global Health; Seattle Children’s Hospital Craniofacial Center; University of Washington School of Dentistry. Human milk banking: African Population Health & Research Center; Alive & Thrive; Human Milk Banking Association of South Africa; KwaZulu-Natal Department of Health; University of Washington Department of Computer Science and Engineering. MSR® SE200™ Community Chlorine Maker: Mountain Safety Research Global Health; World Vision. Nutrition innovations: Aspire; Kintampo Health Research Centre; Kwanme Nkrumah University of Science and Technology; University of Ghana; local communities.

**KEY FUNDERS:** NIFTY cup: Saving Lives at Birth partners: Bill & Melinda Gates Foundation; DFID; Government of Norway; Grand Challenges Canada; Korea International Cooperation Agency; Seattle Children’s Hospital Craniofacial Center; USAID. Human milk banking: Bill & Melinda Gates Foundation; County Innovation Challenge Fund/DFID; Margaret A. Cargill Foundation; individual donors and family foundations. MSR® SE200™ Community Chlorine Maker: Laird Norton Family Foundation; Lemelson Foundation; Washington Global Health Alliance; individual donors and family foundations. Nutrition innovations: Bill & Melinda Gates Foundation.